The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
Authors
Keywords
-
Journal
Viruses-Basel
Volume 13, Issue 7, Pages 1200
Publisher
MDPI AG
Online
2021-06-23
DOI
10.3390/v13071200
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
- (2021) Gregory K. Friedman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development
- (2020) Kathrin Balz et al. Frontiers in Immunology
- Enhancing Antitumor Efficacy of Heavily Vascularized Tumors by RAMBO Virus through Decreased Tumor Endothelial Cell Activation
- (2020) Mitra Nair et al. Cancers
- Design and Rationale for First-In-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors
- (2020) Joshua D. Bernstock et al. HUMAN GENE THERAPY
- Oncolytic herpesvirus therapy for mesothelioma – A Phase I/IIa trial of intrapleural administration of HSV1716
- (2020) Sarah J Danson et al. LUNG CANCER
- Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors
- (2020) Amy Kwan et al. MOLECULAR CANCER THERAPEUTICS
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Perspectives on immunotherapy via oncolytic viruses
- (2019) Alberto Reale et al. Infectious Agents and Cancer
- Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model
- (2019) Francesco Alessandrini et al. ONCOGENE
- Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
- (2019) Iris Koske et al. INTERNATIONAL JOURNAL OF CANCER
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Oncolytic activity of HF10 in head and neck squamous cell carcinomas
- (2019) Shinichi Esaki et al. CANCER GENE THERAPY
- First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial
- (2019) Keri A. Streby et al. MOLECULAR THERAPY
- Engineering strategies to overcome the current roadblocks in CAR T cell therapy
- (2019) Sarwish Rafiq et al. Nature Reviews Clinical Oncology
- Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
- (2019) Jenna H. Newman et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival
- (2019) Paola Sette et al. Molecular Therapy-Oncolytics
- A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer
- (2018) Yoshiki Hirooka et al. BMC CANCER
- Targeting the microenvironment in solid tumors
- (2018) Carmen Belli et al. CANCER TREATMENT REVIEWS
- Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
- (2018) Jason Chesney et al. JOURNAL OF CLINICAL ONCOLOGY
- A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors
- (2018) Valerio Leoni et al. PLoS Pathogens
- Oncolytic herpes simplex virus and immunotherapy
- (2018) Wenqing Ma et al. BMC IMMUNOLOGY
- An oncolytic herpesvirus expressing E-cadherin improves survival in mouse models of glioblastoma
- (2018) Bo Xu et al. NATURE BIOTECHNOLOGY
- PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance
- (2018) Luke Russell et al. Nature Communications
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis
- (2017) Cassie Kline et al. JOURNAL OF NEURO-ONCOLOGY
- Oncolytic Virotherapy: A Contest between Apples and Oranges
- (2017) Stephen J. Russell et al. MOLECULAR THERAPY
- Genomic Signature of the Natural Oncolytic Herpes Simplex Virus HF10 and Its Therapeutic Role in Preclinical and Clinical Trials
- (2017) Ibrahim Ragab Eissa et al. Frontiers in Oncology
- Cooperation of Oncolytic Herpes Virotherapy and PD-1 Blockade in Murine Rhabdomyosarcoma Models
- (2017) Chun-Yu Chen et al. Scientific Reports
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Phase 2 study of concurrent radiotherapy and temozolomide followed by temozolomide and lomustine in the treatment of children with high-grade glioma: a report of the Children's Oncology Group ACNS0423 study
- (2016) Regina I. Jakacki et al. NEURO-ONCOLOGY
- Oncolytic viruses: focusing on the tumor microenvironment
- (2015) C R de Vries et al. CANCER GENE THERAPY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Deletion of a Predicted β-Sheet Domain within the Amino Terminus of Herpes Simplex Virus Glycoprotein K Conserved among Alphaherpesviruses Prevents Virus Entry into Neuronal Axons
- (2015) Nithya Jambunathan et al. JOURNAL OF VIROLOGY
- Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV
- (2015) Lucia Mazzacurati et al. MOLECULAR THERAPY
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
- (2014) Zong Sheng Guo et al. Frontiers in Oncology
- Deciphering and Reversing Tumor Immune Suppression
- (2013) Greg T. Motz et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model
- (2013) T. A. Cheema et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cancer cells
- (2012) H Lin et al. CANCER GENE THERAPY
- An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhancedin vivoantitumor effect against human gastric cancer
- (2012) Toshiaki Tsuji et al. INTERNATIONAL JOURNAL OF CANCER
- TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells
- (2011) M C Anania et al. ONCOGENE
- A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
- (2010) A Nakao et al. CANCER GENE THERAPY
- Chondroitinase ABC I–Mediated Enhancement of Oncolytic Virus Spread and Antitumor Efficacy
- (2010) Nina Dmitrieva et al. CLINICAL CANCER RESEARCH
- Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting
- (2010) Chrisostomi Gialeli et al. FEBS Journal
- Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
- (2010) Sunil K. Geevarghese et al. HUMAN GENE THERAPY
- Transcriptional and Translational Dual-regulated Oncolytic Herpes Simplex Virus Type 1 for Targeting Prostate Tumors
- (2010) Cleo YF Lee et al. MOLECULAR THERAPY
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- Cellular effects of oncolytic viral therapy on the glioblastoma microenvironment
- (2009) P C Huszthy et al. GENE THERAPY
- Enhanced Antitumor Efficacy of Vasculostatin (Vstat120) Expressing Oncolytic HSV-1
- (2009) Jayson Hardcastle et al. MOLECULAR THERAPY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Tissue Inhibitor of Metalloproteinase 3 Suppresses Tumor Angiogenesis in Matrix Metalloproteinase 2-Down-regulated Lung Cancer
- (2008) C. Chetty et al. CANCER RESEARCH
- Tissue Inhibitor of Metalloproteinase-3 via Oncolytic Herpesvirus Inhibits Tumor Growth and Vascular Progenitors
- (2008) Y. Y. Mahller et al. CANCER RESEARCH
- Herpes simplex virus NV1020 as a novel and promising therapy for hepatic malignancy
- (2008) Kaitlyn J Kelly et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
- (2008) Daisuke Watanabe et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2
- (2008) L. Menotti et al. JOURNAL OF VIROLOGY
- Oncolytic HSV-1 Infection of Tumors Induces Angiogenesis and Upregulates CYR61
- (2008) Kazuhiko Kurozumi et al. MOLECULAR THERAPY
- Phase Ib Trial of Mutant Herpes Simplex Virus G207 Inoculated Pre-and Post-tumor Resection for Recurrent GBM
- (2008) James M Markert et al. MOLECULAR THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started